improving outcomes IO

ESMO Asia Virtual Congress 2020 Industry Satellite Symposium

Improving outcomes with immuno-oncology: evolving treatment paradigms for first-line ES-SCLC and unresectable Stage III NSCLC

(CHANNEL 1)

FRIDAY 20 NOVEMBER 12:00–13:30 (SGT); 05:00–06:30 (CET)/ **THURSDAY 19 NOVEMBER** 23:00–00:30 (EST)

- Symposium presentations and panel discussion recordings available for viewing
- Live audience Q&A (30 minutes)
 All recordings will be available for on-demand viewing until Thursday 29 November, 2020

AGENDA & FACULTY

- Emerging immuno-oncology treatment strategies for first-line ES-SCLC (including case study presentation and panel discussion) Myung-Ju Ahn
- The treatment paradigm for unresectable stage III NSCLC: recent clinical advances with immuno-oncology (including case study presentation and panel discussion) Yi-Long Wu
- Audience Q&A Chaired by Martin Reck



Martin Reck (Chair) Department of Thoracic Oncology, German Center for Lung Research, LungenClinic, Grosshansdorf, Germany



Myung-Ju Ahn Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea



Yi-Long Wu Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong, China





\$15.5 million invested in environmental efficiency projects in 2019 (NRRGG fund)



One of three companies worldwide to achieve double A listing for Climate Change and Water Security for four consecutive years



62% of our power is sourced or generated from renewable sources



100% of API (Active Pharmaceutical Ingredient) discharges from AstraZeneca sites were assessed as safe



18% reduction in our water use since 2015



25% of our vehicles in Europe, North America or Japan are hybrid or electric



AstraZeneca is investing up to \$1 billion in a commitment to become carbon neutral by 2025 and carbon negative by 2030. Find out more about AstraZeneca's commitment to sustainability at our website.



This scientific satellite symposium is funded and organised by AstraZeneca VPM ID: CH-3253 | Date of preparation: October 2020 AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK